- Home
- AUDC vs SLN Comparison
AUDC vs SLN Comparison
Compare AUDC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- SLN
- Stock Information
- Founded
- AUDC 1992
- SLN 1994
- Country
- AUDC Israel
- SLN United Kingdom
- Employees
- AUDC N/A
- SLN N/A
- Industry
- AUDC Telecommunications Equipment
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- SLN Health Care
- Exchange
- AUDC Nasdaq
- SLN Nasdaq
- Market Cap
- AUDC 267.0M
- SLN 268.8M
- IPO Year
- AUDC 1999
- SLN N/A
- Fundamental
- Price
- AUDC $9.03
- SLN $7.20
- Analyst Decision
- AUDC Buy
- SLN Buy
- Analyst Count
- AUDC 3
- SLN 6
- Target Price
- AUDC $11.67
- SLN $39.67
- AVG Volume (30 Days)
- AUDC 82.5K
- SLN 142.6K
- Earning Date
- AUDC 11-04-2025
- SLN 11-13-2025
- Dividend Yield
- AUDC 4.43%
- SLN N/A
- EPS Growth
- AUDC 3.22
- SLN N/A
- EPS
- AUDC 0.46
- SLN N/A
- Revenue
- AUDC $243,249,000.00
- SLN $27,169,000.00
- Revenue This Year
- AUDC $2.52
- SLN N/A
- Revenue Next Year
- AUDC $1.74
- SLN N/A
- P/E Ratio
- AUDC $19.30
- SLN N/A
- Revenue Growth
- AUDC N/A
- SLN 22.28
- 52 Week Low
- AUDC $7.70
- SLN $1.97
- 52 Week High
- AUDC $12.72
- SLN $18.72
- Technical
- Relative Strength Index (RSI)
- AUDC 36.58
- SLN 70.80
- Support Level
- AUDC $8.83
- SLN $5.00
- Resistance Level
- AUDC $9.67
- SLN $5.83
- Average True Range (ATR)
- AUDC 0.26
- SLN 0.52
- MACD
- AUDC -0.06
- SLN 0.20
- Stochastic Oscillator
- AUDC 18.22
- SLN 79.22
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.